

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 May 2013

Section H cumulative for April and May 2013



Contents

Summary of PHARMAC decisions effective 1 May 2013	3
Amendment to restrictions for ciprofloxacin tablets and clindamycin.....	3
New brand of ACE inhibitor fully subsidised	4
Tacrolimus – decision pending.....	5
Levonorgestrel tab 1.5 mg – Sole Subsidised Supply.....	5
Pedialyte plain and fruit flavours to be discontinued	5
News in brief.....	5
Tender News.....	6
Looking Forward	6
Sole Subsidised Supply products cumulative to May 2013.....	7
New Listings.....	19
Changes to Restrictions	20
Changes to Subsidy and Manufacturer’s Price.....	22
Changes to General Rules.....	23
Changes to Brand Name	25
Changes to Section I	26
Delisted Items	27
Items to be Delisted	29
Section H changes to Part II	30
Index.....	33

Summary of PHARMAC decisions

EFFECTIVE 1 MAY 2013

New listings (page 19)

- Perindopril (Apo-Perindopril) tab 2 mg and 4 mg
- Clonidine hydrochloride (Clonidine BNM) tab 25 mcg
- Metolazone (Zaroxolyn) tab 5 mg – S29 – Special Authority – Retail pharmacy
- Hydralazine hydrochloride (Onelink) tab 25 mg – S29 – Special Authority – Retail pharmacy
- Lidocaine [lignocaine] hydrochloride (Lidocaine-Claris) inj 2%, 5ml and 2%, 20 ml
- Pharmacy services (BSF Apo-Diltiazem CD) Brand switch fee

Changes to restrictions (pages 20-21)

- Perindopril (Coversyl) tab 2 mg and 4 mg – removal of higher subsidy by endorsement
- Trandolapril (Gopten) cap 1 mg and 2 mg – rewording of higher subsidy by endorsement
- Diltiazem hydrochloride (Apo-Diltiazem CD) cap long-acting 120 mg, 180 mg and 240 mg – addition of brand switch fee payable
- Ciprofloxacin tab 250 mg, 500 mg and 750 mg – amendment to restriction
- Clindamycin cap hydrochloride 150 mg and inj phosphate 150 mg per ml, 4 ml – amendment to restriction
- Itraconazole cap 100 mg – amendment to restriction
- Isoniazid tab 100 mg, tab 100 mg with rifampicin 150 mg and tab 150 mg with rifampicin 300 mg – amendment to restriction
- Lignocaine hydrochloride to lidocaine [lignocaine] hydrochloride – amendment to chemical name

Decreased subsidy (page 22)

- Levonorgestrel (Postinor-1) tab 1.5 mg
- Codeine phosphate (PSM) tab 15 mg, 30 mg and 60 mg
- Amisulpride (Solian) tab 100 mg, 200 mg, 400 mg and oral liq 100 mg per ml

Increased subsidy (page 22)

- Perindopril (Coversyl) tab 2 mg and 4 mg

Amendment to restrictions for ciprofloxacin tablets and clindamycin

Changes to the restrictions on some antibiotics were made last month (1 April 2013) to reflect proposed new prescribing rules in hospitals which will take effect from 1 July 2013. From 1 May 2013 these are being amended as follows:

- For ciprofloxacin, the endorsement restriction will be removed from all tablet presentations and will be replaced by a prescribing guideline.
- For clindamycin, the specified specialist type will be removed, but the Retail pharmacy-Specialist restriction will remain.

These changes are being made to allow prescribers more time to implement appropriate changes to their prescribing



practices and we will work with the sector to do this.

Whilst this change doesn't come into effect until 1 May 2013, we would encourage pharmacists to apply these changes to current prescriptions. Audit and Compliance at Sector Services are aware of PHARMACs recommendations.

This will reduce the administrative burden for pharmacists

New brand of ACE inhibitor fully subsidised

Apo-Perindopril (perindopril tab 2 mg and 4 mg) will be fully subsidised from 1 May 2013. The higher subsidy by endorsement for the Coversyl brand for patients with congestive heart failure, who were taking perindopril prior to 1 June 1998, will be removed. From 1 May 2013 any patient currently receiving the higher subsidy by endorsement will need to switch to the Apo-Perindopril brand to remain on a fully subsidised product.



Tacrolimus – decision pending

PHARMAC consulted on a proposal in December 2012 to list Sandoz's brand of tacrolimus capsules from 1 March 2013. The proposal also proposed to award Sole Subsidised Supply Status (the only funded brand in the community) and Hospital Supply Status (the only available brand in DHB hospitals, subject to a 1% discretionary variance limit) to Tacrolimus Sandoz from 1 September 2013 to 31 August 2017. A decision has not yet been made by PHARMAC.

Levonorgestrel tab 1.5 mg – Sole Subsidised Supply

From 1 May 2013, the price and subsidy of Postinor-1 (levonorgestrel) 1.5 mg tablets will decrease and Sole Supply on this brand will commence 1 October 2013. The Next Choice brand (2 x 750 mcg tablets) will have a subsidy reduction from 1 July 2013 and be delisted on 1 October 2013.

Pedialyte plain and fruit flavours to be discontinued

The plain and fruit flavours of Pedialyte electrolyte solution are to be discontinued. The supplier, Abbott Laboratories, has notified this is due to a global discontinuation and would result in bubblegum being the only flavour listed in the Pharmaceutical Schedule. The date of discontinuation is yet to be confirmed.

News in brief

- The chemical name for **lignocaine hydrochloride** will be changed to **lidocaine [lignocaine] hydrochloride** from 1 May 2013.
- A Brand Switch Fee will apply to dispensings of Apo-Diltiazem CD, **diltazem hydrochloride** long-acting 120 mg, 180 mg and 240 mg capsules from 1 May 2013 to 1 August 2013.
- Phlexy 10 (**aminoacid formula without phenylalanine**) tropical sachets will be delisted 1 November 2013 due to supplier discontinuation.
- From 1 May 2013, the price of the Home Essential brand of **calamine** cream 100 g will increase. The Pharmacy Health brand remains fully subsidised.
- The brand name of Goldshield's **levothyroxine** tab 50 mcg and 100 mcg will change from Goldshield to Mercury Pharma.
- The Nupentin brand of **gabapentin** 400 mg capsule will be supplied in bottles instead of blisters. There is a new Pharmacode for the bottled packs and these will be subsidised from 1 May 2013. The 100 mg and 300 mg strengths of Nupentin changed to bottles from 1 September 2012.
- **Sodium cromoglycate** (Rex) nasal spray, 4% will be delisted 1 November 2013 due to supplier discontinuation.

Tender News

Sole Subsidised Supply changes – effective 1 June 2013

Chemical Name	Presentation; Pack size	Sole Subsidised Supply brand (and supplier)
Bezafibrate	Tab 200 mg; 90 tab	Bezalip (Activis)
Diclofenac sodium	Tab EC 25 mg; 100 tab	Apo-Diclo (Apotex)
Diclofenac sodium	Tab EC 50 mg; 500 tab	Apo-Diclo (Apotex)
Domperidone	Tab 10 mg; 100 tab	Prokinex (Airflow)
Promethazine hydrochloride	Oral liq 5 mg per 5 ml; 100 ml	Allersoothe (AFT)
Oxycodone hydrochloride	Inj 50 mg per ml, 1 ml; 5 inj	OxyNorm (MundiPharm)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels.

Possible decisions for future implementation 1 June 2013

- Carbomer (Poly Gel) ophthalmic gel 0.2%, 30 x 0.5 g – new listing – Special Authority – Retail pharmacy
- Hypromellose with dextran (Poly-Tears) eye drops 0.3% with dextran 0.1%, 15 ml OP – subsidy and price decrease, and reference pricing of Methopt and Vistil brands
- Sodium hyaluronate (Hylo-Fresh) eye drops 1 mg per ml, 10 ml OP – new listing – Special Authority – Retail pharmacy
- Ticagrelor (Brilinta) tab 90 mg – new listing – Special Authority – Retail Pharmacy

Sole Subsidised Supply Products – cumulative to May 2013

Generic Name	Presentation	Brand Name	Expiry Date*
Abacavir sulphate	Oral liq 20 mg per ml Tab 300 mg	Ziagen Ziagen	2014
Acarbose	Tab 50 mg and 100 mg	Accarb	2015
Acetazolamide	Tab 250 mg	Diamox	2014
Acetylcysteine	Inj 200 mg per ml, 10 ml	Martindale Acetylcysteine	2015
Aciclovir	Tab dispersible 200 mg, 400 mg & 800 mg	Lovir	2013
Allopurinol	Tab 100 mg & 300 mg	Apo-Allopurinol	2014
Amantadine hydrochloride	Cap 100 mg	Symmetrel	2014
Aminophylline	Inj 25 mg per ml, 10 ml	DBL Aminophylline	2014
Amitriptyline	Tab 10 mg Tab 25 mg & 50 mg	Arrow-Amitriptyline Amitrip	2014
Amlodipine	Tab 2.5 mg Tab 5 mg & 10 mg	Apo-Amlodipine Apo-Amlodipine	2014
Amoxicillin	Inj 250 mg, 500 mg & 1 g Cap 250 mg & 500 mg	Ibiamox Alphamox	2014 2013
Amoxicillin clavulanate	Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml	Augmentin	2015
	Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml	Augmentin	
	Tab 500 mg with potassium clavulanate 125 mg	Curam Duo	2014
Aqueous cream	Crm	AFT	2014
Ascorbic acid	Tab 100 mg	Vitala-C	2013
Aspirin	Tab 100 mg Tab dispersible 300 mg	Ethics Aspirin EC Ethics Aspirin	2013
Atenolol	Tab 50 mg & 100 mg	Mylan Atenolol	2015
Atorvastatin	Tab 10 mg, 20 mg, 40 mg & 80 mg	Zarator	2015
Atropine sulphate	Inj 600 mcg, 1 ml	AstraZeneca	2015
Azathioprine	Tab 50 mg	Imuprine	2013
	Inj 50 mg	Imuran	
Azithromycin	Tab 500 mg	Apo-Azithromycin	2015
Bendrofluzide	Tab 2.5 mg & 5 mg	Arrow- Bendrofluzide	2014
Benzathine benzylpenicillin	Inj 1.2 mega u per 2.3 ml	Bicillin LA	2015
Benzylpenicillin sodium (Penicillin G)	Inj 600 mg	Sandoz	2014
Betaxolol hydrochloride	Eye drops 0.5%	Betoptic	2014
	Eye drops 0.25%	Betoptic S	

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2013

Generic Name	Presentation	Brand Name	Expiry Date*
Bezafibrate	Tab long-acting 400 mg	Bezalip Retard	2015
Bicalutamide	Tab 50 mg	Bicalaccord	2014
Bisacodyl	Tab 5 mg	Lax-Tab	2013
Bisoprolol fumarate	Tab 2.5 mg, 5 mg & 10 mg	Bosvate	2013
Blood glucose diagnostic test meter	Meter with 50 lancets, a lancing device and 10 diagnostic test strips	CareSens N CareSens N POP CareSens II	2015
Blood glucose diagnostic test strip	Blood glucose test strips	CareSens CareSens N	2015
Brimonidine tartrate	Eye drops 0.2%	Arrow-Brimonidine	2014
Cabergoline	Tab 0.5 mg	Dostinex	2015
Calamine	Lotn, BP	PSM	2015
Calcitonin	Inj 100 iu per ml, 1 ml	Miacalcic	2014
Calcium carbonate	Tab 1.25 g (500 mg elemental) Tab eff 1.75 g (1 g elemental)	Arrow-Calcium Calsource	2014
Calcium folinate	Tab 15 mg	DBL Leucovorin Calcium	2014
Candesartan	Tab 4 mg, 8 mg, 16 mg & 32 mg	Candestar	2015
Captopril	Tab 12.5 mg, 25 mg & 50 mg Oral liq 5 mg per ml	m-Captopril Capoten	2013
Cefaclor monohydrate	Grans for oral liq 125 mg per 5 ml	Ranbaxy-Cefaclor	2013
Cefazolin sodium	Inj 500 mg & 1 g	AFT	2014
Ceftriaxone sodium	Inj 500 mg Inj 1 g	Veracol Aspen Ceftriaxone	2013
Cefuroxime sodium	Inj 750 mg	Multichem	2014
Cetomacrogol	Crn BP	PSM	2013
Cetirizine hydrochloride	Oral liq 1 mg per ml Tab 10 mg	Cetirizine - AFT Zetop	2014
Chloramphenicol	Eye oint 1% Eye drops 0.5%	Chlorsig Chlorafast	2015
Chlorhexidine gluconate	Mouthwash 0.2% Handrub 1% with ethanol 70% Soln 4%	healthE healthE Orion	2015 2014
Ciclopirox olamine	Nail-soln 8%	Apo-Ciclopirox	2015
Cilazapril	Tab 0.5 mg, 2.5 mg & 5 mg	Zapril	2013
Cilazapril with hydrochlorothiazide	Tab 5 mg with hydrochlorothiazide 12.5 mg	Inhibace Plus	2013
Ciprofloxacin	Tab 250 mg, 500 mg & 750 mg	Cipflox	2014
Citalopram hydrobromide	Tab 20 mg	Arrow-Citalopram	2014

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2013

Generic Name	Presentation	Brand Name	Expiry Date*
Clarithromycin	Tab 500 mg Tab 250 mg	Apo-Clarithromycin Apo-Clarithromycin	2014
Clindamycin	Cap hydrochloride 150 mg	Clindamycin ABM	2013
Clomipramine hydrochloride	Tab 10 mg & 25 mg	Apo-Clomipramine	2015
Clonidine hydrochloride	Tab 150 mcg Inj 150 mcg per ml, 1 ml	Catapres	2015
Clopidogrel	Tab 75 mg	Apo-Clopidogrel	2013
Clotrimazole	Crm 1%	Clomazol	2014
	Vaginal crm 1% with applicator	Clomazol	2013
	Vaginal crm 2% with applicator	Clomazol	
Coal tar	Soln BP	Midwest	2013
Colchicine	Tab 500 mcg	Colgout	2013
Compound electrolytes	Powder for soln for oral use 4.4 g	Electral	2013
Crotamiton	Crm 10%	Itch-Soothe	2015
Cyclizine hydrochloride	Tab 50 mg	Nausicalm	2015
Cyclophosphamide	Tab 50 mg	Cycloblastin	2013
Cyclosporin	Oral liq 100 mg per ml	Neoral	2015
Cyproterone acetate	Tab 50 mg & 100 mg	Siterone	2015
Cyproterone acetate with ethinyloestradiol	Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs	Ginet 84	2014
Desmopressin	Nasal spray 10 mcg per dose	Desmopressin-PH&T	2014
Dexamethasone	Tab 1 mg & 4 mg	Douglas	2015
	Eye oint 0.1%	Maxidex	2014
	Eye drops 0.1%	Maxidex	2013
Dexamethasone sodium phosphate	Inj 4 mg per ml, 1 ml & 2 ml	Hospira	2013
Dexamethasone with neomycin and polymyxin b sulphate	Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g	Maxitrol	2014
	Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml	Maxitrol	
Dexamphetamine sulphate	Tab 5 mg	PSM	2015
Dextrose	Inj 50%, 10 ml	Biomed	2014
Dextrose with electrolytes	Soln with electrolytes	Pedialyte – Fruit Pedialyte – Bubblegum Pedialyte – Plain	2013

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2013

Generic Name	Presentation	Brand Name	Expiry Date*
Diclofenac sodium	Tab long-acting 75 mg & 100 mg	Diclax SR	2015
	Inj 25 mg per ml, 3 ml	Voltaren	2014
	Eye drops 1 mg per ml	Voltaren Ophtha	
	Suppos 12.5 mg, 25 mg, 50 mg & 100 mg	Voltaren	
Dihydrocodeine tartrate	Tab long-acting 60 mg	DHC Continus	2013
Diltiazem hydrochloride	Cap long-acting 120 mg, 180 mg & 240 mg	Apo-Diltiazem CD	2015
	Tab 30 mg & 60 mg	Dilzem	
Dipyridamole	Tab long-acting 150 mg	Pytazen SR	2014
Docusate sodium	Cap 50 mg	Laxofast 50	2014
	Cap 120 mg	Laxofast 120	
Docusate sodium with sennosides	Tab 50 mg with total sennosides 8 mg	Laxsol	2013
Doxazosin mesylate	Tab 2 mg & 4 mg	Apo-Doxazosin	2014
Doxycycline hydrochloride	Tab 100 mg	Doxine	2014
Emulsifying ointment	Oint BP	AFT	2014
Enalapril	Tab 5 mg, 10 mg & 20 mg	m-Enalapril	2015
Enoxaparin sodium	Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg	Clexane	2015
Entacapone	Tab 200 mg	Entapone	2015
Ergometrine maleate	Inj 500 mcg per ml, 1 ml	DBL Ergometrine	2014
Escitalopram	Tab 10 mg & 20 mg	Loxalate	2013
Etidronate disodium	Tab 200 mg	Arrow-Etidronate	2015
Ethinylestradiol	Tab 10 mcg	NZ Medical and Scientific	2015
Ethinylestradiol with levonorgestrel	Tab 20 mcg with levonorgestrel 100 mcg & 7 inert tab	Ava 20 ED	2014
	Tab 30 mcg with levonorgestrel 150 mcg & 7 inert tab	Ava 30 ED	
Exemestane	Tab 25 mg	Aromasin	2014
Felodopine	Tab long-acting 5 mg & 10 mg	Plendil ER	2015
	Tab long-acting 2.5 mg	Plendil ER	
Fentanyl	Transdermal patch 12.5 mcg per hour, 25 mcg per hour, 50 mcg per hour, 75 mcg per hour, 100 mcg per hour	Mylan Fentanyl Patch	2013
Fentanyl citrate	Inj 50 mcg per ml, 2 ml & 10 ml	Boucher and Muir	2015
Ferrous sulphate	Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml)	Ferodan	2013
Filgrastim	Inj 300 mcg per 0.5 ml	Zarzio	31/12/15
	Inj 480 mcg per 0.5 ml	Zarzio	

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2013

Generic Name	Presentation	Brand Name	Expiry Date*
Finasteride	Tab 5 mg	Rex Medical	2014
Flucloxacillin sodium	Grans for oral liq 125 mg per 5 ml	AFT	2015
	Grans for oral liq 250 mg per 5 ml		
	Cap 250 mg & 500 mg	Staphlex	
	Inj 250 mg, 500 mg & 1 g	Flucloxin	2014
Fluconazole	Cap 50 mg, 150 mg & 200 mg	Ozole	2014
Fluorometholone	Eye drops 0.1%	Flucon	2015
Fluorouracil sodium	Crn 5%	Efudix	2015
Fluoxetine hydrochloride	Cap 20 mg	Fluox	2013
	Tab dispersible 20 mg, scored	Fluox	
Flutamide	Tab 250 mg	Flutamin	2013
Fluticasone propionate	Metered aqueous nasal spray, 50 mcg per dose	Flixonase Hayfever & Allergy	2015
Furosemide	Tab 500 mg	Urex Forte	2015
	Tab 40 mg	Diurin 40	
	Inj 10 mg per ml, 2 ml	Frusemide-Claris	2013
Fusidic acid	Crn 2%	Foban	2013
	Oint 2%	Foban	
Gemfibrozil	Tab 600 mg	Lipazil	2013
Gentamicin sulphate	Inj 40 mg per ml, 2 ml	Pfizer	2015
Gliclazide	Tab 80 mg	Apo-Gliclazide	2014
Glipizide	Tab 5 mg	Minidiab	2015
Glycerol	Suppos 3.6 g	PSM	2015
	Liquid	healthE	2013
Glyceryl trinitrate	Aerosol spray 400 mcg per dose	Glytrin	2014
	TDDS 5 mg & 10 mg	Nitroderm TTS	
	Tab 600 mcg	Lycinate	
Haloperidol	Inj 5 mg per ml, 1 ml	Serenace	2013
	Oral liq 2 mg per ml	Serenace	
	Tab 500 mcg, 1.5 mg & 5 mg	Serenace	
Hydrocortisone	Tab 5 mg & 20 mg	Douglas	2015
	Crn 1%	Pharmacy Health	2014
	Powder	ABM	
	Inj 50 mg per ml, 1 ml	Solu-Cortef	2013
Hydrocortisone acetate	Rectal foam 10%, CFC-Free (14 applications)	Colifoam	2015
Hydrocortisone butyrate	Lipocream 0.1%	Locoid Lipocream	2015
	Milky emul 0.1%	Locoid Crelo	
	Oint 0.1%	Locoid	
	Scalp lotn 0.1%	Locoid	
Hydrocortisone with miconazole	Crn 1% with miconazole nitrate 2%	Micreme H	2013

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2013

Generic Name	Presentation	Brand Name	Expiry Date*
Hydrocortisone with wool fat and mineral oil	Lotn 1% with wool fat hydrous 3% and mineral oil	DP Lotn HC	2014
Hydroxocobalamin	Inj 1 mg per ml, 1 ml	ABM Hydroxocobalamin	2015
Hydroxychloroquine sulphate	Tab 200 mg	Plaquenil	2015
Hyoscine N-butylbromide	Inj 20 mg, 1 ml Tab 10 mg	Buscopan Gastrosoothe	2014
Ibuprofen	Tab 200 mg	Arrowcare	2014
	Tab long-acting 800 mg	Brufen SR	
	Oral liq 100 mg per 5 ml	Fenpaed	2013
Imiquimod	Crn 5%	Aldara	2014
Indapamide	Tab 2.5 mg	Dapa-Tabs	2013
Ipratropium bromide	Aqueous nasal spray, 0.03%, 15 ml OP	Univent	2013
	Nebuliser soln, 250 mcg per ml, 1 ml & 2 ml	Univent	
Iron polymaltose	Inj 50 mg per ml, 2 ml	Ferrum H	2014
Isoniazid	Tab 100 mg	PSM	2015
Isosorbide mononitrate	Tab 20 mg	Ismo 20	2014
	Tab long-acting 40 mg	Corangin	
Isotretinoin	Cap 10 mg & 20 mg	Oratane	2015
Itraconazole	Cap 100 mg	Itrazole	2013
Ketoconazole	Shampoo 2%	Sebizole	2014
Lactulose	Oral liq 10 g per 15 ml	Laevolac	2013
Lamivudine	Tab 100 mg	Zetlam	2014
	Oral liq 10 mg per ml	3TC	2013
	Tab 150 mg	3TC	
Lansoprazole	Cap 15 mg & 30 mg	Solox	2015
Latanoprost	Eye drops 50 mcg per ml	Hysite	2015
Letrozole	Tab 2.5 mg	Letraccord	2015
Levonorgestrel	Subdermal implant (2 x 75 mg rods)	Jadelle	31/12/13
Lignocaine hydrochloride	Viscous soln 2%	Xylocaine Viscous	2014
	Inj 1%, 5 ml & 20 ml	Xylocaine	2013
Lignocaine with prilocaine	Crn 2.5% with prilocaine 2.5% (5 g tubes)	EMLA	2013
	Crn 2.5% with prilocaine 2.5%; 30 g OP	EMLA	
Lisinopril	Tab 5 mg, 10 mg & 20 mg	Arrow-Lisinopril	2015
Lithium carbonate	Tab 250 mg & 400 mg	Lithicarb FC	2015
	Cap 250 mg	Douglas	2014

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2013

Generic Name	Presentation	Brand Name	Expiry Date*
Lodoxamide trometamol	Eye drops 0.1%	Lomide	2014
Loperamide hydrochloride	Cap 2 mg	Diamide Relief	2013
Loratadine	Oral liq 1 mg per ml Tab 10 mg	Lorapaed Loraclear Hayfever Relief	2013
Lorazepam	Tab 1 mg & 2.5 mg	Ativan	2013
Losartan	Tab 12.5 mg, 25 mg, 50 mg & 100 mg	Lostaar	2014
Losartan with hydrochlorothiazide	Tab 50 mg with hydrochlorothiazide 12.5 mg	Arrow-Losartan & Hydrochlorothiazide	2014
Macrogol 3350	Powder 13.125 g, sachets	Lax-Sachets	2014
Malathion	Liq 0.5% Shampoo 1%	A-Lices A-Lices	2013
Mask for spacer device	Size 2	EZ-fit Paediatric Mask	2015
Mebendazole	Tab 100 mg	De-Worm	2014
Mebeverine hydrochloride	Tab 135 mg	Colofac	2014
Megestrol acetate	Tab 160 mg	Apo-Megestrol	2015
Methylprednisolone	Tab 4 mg & 100 mg	Medrol	2015
Methylprednisolone acetate	Inj 40 mg per ml	Depo-Medrol	2015
Methylprednisolone acetate with lignocaine	Inj 40 mg per ml with lignocaine 1 ml	Depo-Medrol with Lidocaine	2015
Mercaptopurine	Tab 50 mg	Purinethol	2013
Mesalazine	Enema 1 g per 100 ml Suppos 500 mg	Pentasa Asacol	2015 2014
Metformin hydrochloride	Tab immediate-release 500 mg & 850 mg	Apotex	2015
Methadone hydrochloride	Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 5 mg	Biodone Biodone Forte Biodone Extra Forte Methatabs	2015 2013
Methotrexate	Inj 25 mg per ml, 2 ml & 20 ml	Hospira	2013
Methylprednisolone sodium succinate	Inj 40 mg per ml, 1 ml; 62.5 mg per ml, 2 ml; 500 mg & 1 g	Solu-Medrol	2015
Metoclopramide hydrochloride	Inj 5 mg per ml, 2 ml Tab 10 mg	Pfizer Metamide	2014
Metoprolol succinate	Tab long-acting 23.75 mg, 47.5 mg, 95 mg & 190 mg	Metoprolol-AFT CR	2015
Metoprolol tartrate	Inj 1 mg per ml, 5 ml Tab 50 mg & 100 mg Tab long-acting 200 mg	Lopresor Lopresor Slow-Lopresor	2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2013

Generic Name	Presentation	Brand Name	Expiry Date*
Miconazole	Oral gel 20 mg per g	Decozol	2015
Miconazole nitrate	Crn 2%	Multichem	2014
Mirtazapine	Tab 30 mg & 45 mg	Avanza	2015
Moclobemide	Tab 150 mg & 300 mg	Apo-Moclobemide	2015
Mometasone furoate	Crn 0.1% Oint 0.1%	m-Mometasone	2015
Morphine hydrochloride	Oral liq 1 mg per ml, 2 mg per ml, 5 mg per ml & 10 mg per ml	RA-Morph	2015
Morphine sulphate	Inj 5 mg per ml, 1 ml	DBL Morphine Sulphate	2014
	Inj 10 mg per ml, 1 ml	DBL Morphine Sulphate	
	Inj 15 mg per ml, 1 ml	DBL Morphine Sulphate	
	Inj 30 mg per ml, 1 ml	DBL Morphine Sulphate	
	Tab long-acting 10 mg, 30 mg, 60 mg & 100 mg Cap long-acting 10 mg, 30 mg, 60 mg & 100 mg	Arrow-Morphine LA m-Elson	2013
Morphine tartrate	Inj 80 mg per ml, 1.5 ml & 5 ml	Hospira	2013
Mucilaginous laxatives	Dry	Konsyl-D	2013
Naphazoline hydrochloride	Eye drops 0.1%	Naphcon Forte	2014
Nadolol	Tab 40 mg & 80 mg	Apo-Nadolol	2015
Naproxen	Tab 250 mg	Noflam 250	2015
	Tab 500 mg	Noflam 500	
Naltrexone hydrochloride	Tab 50 mg	Naltraccord	2013
Neostigmine	Inj 2.5 mg per ml, 1 ml	AstraZeneca	2014
Nevirapine	Tab 200 mg	Nevirapine Alphapharm	2015
Nicotine	Gum 2 mg & 4 mg (classic, fruit, mint)	Habitrol	2014
	Lozenge 1 mg & 2 mg	Habitrol	
	Patch 7 mg, 14 mg & 21 mg	Habitrol	
Nicotinic acid	Tab 50 mg & 500 mg	Apo-Nicotinic Acid	2014
Norfloxacin	Tab 400 mg	Arrow-Norfloxacin	2014
Norethisterone	Tab 350 mcg	Noriday 28	2015
	Tab 5 mg	Primolut N	2014
Nystatin	Oral liq 100,000 u per ml	Nilstat	2014
	Cap 500,000 u	Nilstat	2013
	Tab 500,000 u	Nilstat	
Octreotide (somatostatin analogue)	Inj 50 mcg per ml, 1 ml	Octreotide Max Rx	2014
	Inj 100 mcg per ml, 1 ml		
	Inj 500 mcg per ml, 1 ml		

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2013

Generic Name	Presentation	Brand Name	Expiry Date*
Oil in water emulsion	Crn	healthE Fatty Cream	2015
Omeprazole	Cap 10 mg, 20 mg & 40 mg Powder Inj 40 mg	Omezol Relief Midwest Dr Reddy's Omeprazole	2014
Ondansetron	Tab disp 8 mg Tab 4 mg & 8 mg	Dr Reddy's Ondansetron Dr Reddy's Ondansetron	2013
Oxazepam	Tab 10 mg & 15 mg	Ox-Pam	2014
Oxycodone hydrochloride	Inj 10 mg per ml, 1 ml & 2 ml	Oxycodone Orion	2015
Oxytocin	Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml	Syntometrine	2015
Pamidronate disodium	Inj 3 mg per ml, 10 ml; 6 mg per ml, 10 ml & 9 mg per ml, 10 ml	Pamidronate BNM	2014
Pantoprazole	Inj 40 mg Tab 20 mg & 40 mg	Pantocid IV Dr Reddy's Pantoprazole	2014 2013
Paracetamol	Suppos 500 mg Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml	Paracare Parafast Ethics Paracetamol Paracare Double Strength	2015 2014
Paracetamol with codeine	Tab paracetamol 500 mg with codeine phosphate 8 mg	Paracetamol + Codeine (Relieve)	2014
Paraffin liquid with soft white paraffin	Eye oint with soft white paraffin	Lacri-Lube	2013
Paroxetine hydrochloride	Tab 20 mg	Loxamine	2013
Peak flow meter	Low range & normal range	Breath-Alert	2015
Pergolide	Tab 0.25 mg & 1 mg	Permax	2014
Permethrin	Crn 5% Lotn 5%	Lyderm A-Scabies	2014
Pethidine hydrochloride	Tab 50 mg & 100 mg Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml	PSM DBL Pethidine Hydrochloride DBL Pethidine Hydrochloride	2015 2014
Phenobarbitone	Tab 15 mg & 30 mg	PSM	2015
Phenoxymethylpenicillin (Pencillin V)	Cap potassium salt 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml	Cilicaine VK AFT AFT	2013
Pioglitazone	Tab 15 mg, 30 mg & 45 mg	Pizaccord	2015

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2013

Generic Name	Presentation	Brand Name	Expiry Date*
Pizotifen	Tab 500 mcg	Sandomigran	2015
Poloxamer	Oral drops 10%	Coloxyl	2014
Potassium chloride	Tab long-acting 600 mg	Span-K	2015
Pramipexole hydrochloride	Tab 0.125 mg & 0.25 mg	Dr Reddy's Pramipexole	2013
Pravastatin	Tab 20 mg & 40 mg	Cholvastin	2014
Procaine penicillin	Inj 1.5 mega u	Cilicaine	2014
Promethazine hydrochloride	Tab 10 mg & 25 mg	Allersoothe	2015
Pyridostigmine bromide	Tab 60 mg	Mestinon	2014
Pyridoxine hydrochloride	Tab 25 mg Tab 50 mg	PyridoxADE Apo-Pyridoxine	2014
Quinapril with hydrochlorothiazide	Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg	Accuretic 10 Accuretic 20	2015
Ranitidine hydrochloride	Oral liq 150 mg per 10 ml Tab 150 mg & 300 mg	Peptisoothe Arrow-Ranitidine	2014
Rifabutin	Cap 150 mg	Mycobutin	2013
Ritonavir	Tab 100 mg	Norvir	2015
Rizatriptan	Tab orodispersible 10 mg	Rizamelt	2014
Ropinirole hydrochloride	Tab 0.25 mg, 1 mg, 2 mg & 5 mg	Ropin	2013
Roxithromycin	Tab 150 mg & 300 mg	Arrow-Roxithromycin	2015
Salbutamol	Nebuliser soln, 1 mg per ml & 2 mg per ml, 2.5 ml	Asthalin	2015
Salbutamol with ipratropium bromide	Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml	Duolin	2015
Sertraline	Tab 50 mg & 100 mg	Arrow-Sertraline	2013
Sildenafil	Tab 25 mg, 50 mg & 100 mg	Silagra	2014
Simvastatin	Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg	Arrow-Simva 10mg Arrow-Simva 20mg Arrow-Simva 40mg Arrow-Simva 80mg	2014
Sodium chloride	Inj 23.4%, 20 ml	Biomed	2013
Sodium citrate with sodium lauryl sulphoacetate	Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml	Micolette	2013
Sodium citro-tartrate	Grans effervescent 4 g sachets	Ural	2013
Sodium cromoglycate	Eye drops 2%	Rexacrom	2013

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2013

Generic Name	Presentation	Brand Name	Expiry Date*
Spacer device	800 ml 230 ml (single patient)	Volumatic Space Chamber Plus	2015
Spironolactone	Tab 25 mg & 100 mg	Spirotone	2013
Sumatriptan	Inj 12 mg per ml, 0.5 ml Tab 50 mg & 100 mg	Arrow-Sumatriptan Arrow-Sumatriptan	2013
Tamoxifen citrate	Tab 20 mg	Genox	2014
Tamsulosin hydrochloride	Cap 400 mcg	Tamsulosin-Rex	2013
Tar with triethanolamine lauryl sulphate and fluorescein	Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium, 500 ml & 1,000 ml	Pinetarsol	2014
Temazepam	Tab 10 mg	Normison	2014
Temozolomide	Cap 5 mg, 20 mg, 100 mg & 250 mg	Temaccord	2013
Terazosin hydrochloride	Tab 1 mg, 2 mg & 5 mg	Arrow	2013
Terbinafine	Tab 250 mg	Dr Reddy's Terbinafine	2014
Testosterone cypionate	Inj long-acting 100 mg per ml, 10 ml	Depo-Testosterone	2014
Testosterone undecanoate	Cap 40 mg	Andriol Testocaps	2015
Tetrabenazine	Tab 25 mg	Motetis	2013
Tetracosactrin	Inj 250 mcg Inj 1 mg per ml, 1 ml	Synacthen Synacthen Depot	2014
Timolol maleate	Eye drops 0.25% & 0.5%	Arrow-Timolol	2014
Tobramycin	Eye drops 0.3% Eye oint 0.3% Inj 40 mg per ml, 2 ml	Tobrex Tobrex DBL Tobramycin	2014
Tolcapone	Tab 100 mg	Tasmar	2014
Tramadol hydrochloride	Cap 50 mg	Arrow-Tramadol	2014
Triamcinolone acetonide	Inj 10 mg per ml, 1 ml Inj 40 mg per ml, 1 ml Crm 0.02% Oint 0.02% 0.1% in Dental Paste USP	Kenacort-A Kenacort-A40 Aristocort Aristocort Oracort	2014
Tranexamic acid	Tab 500 mg	Cyklokapron	2013
Tropicamide	Eye drops 0.5% & 1%	Mydriacyl	2014
Ursodeoxycholic acid	Cap 250 mg	Ursosan	2014
Vancomycin hydrochloride	Inj 500 mg	Mylan	2014
Verapamil hydrochloride	Tab 40 mg & 80 mg	Isoptin	2014
Vitamin B complex	Tab, strong, BPC	B-PlexADE	2013
Vitamins	Tab (BPC cap strength)	MultiADE	2013

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to May 2013

Generic Name	Presentation	Brand Name	Expiry Date*
Zidovudine [AZT]	Cap 100 mg Oral liq 10 mg per ml	Retrovir Retrovir	2013
Zidovudine [AZT] with lamivudine	Tab 300 mg with lamivudine 150 mg	Alphapharm	2014
Zinc and castor oil	Oint BP	Multichem	2014
Zinc sulphate	Caps 137.4 mg (50 mg elemental)	Zincaps	2014

May changes in bold

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings

Effective 1 May 2013

52	PERINDOPRIL				
	* Tab 2 mg	3.75	30	✓ Apo-Perindopril	
	* Tab 4 mg	4.80	30	✓ Apo-Perindopril	
57	CLONIDINE HYDROCHLORIDE				
	* Tab 25 mcg.....	15.09	112	✓ Clonidine BNM	
58	METOLAZONE – Special Authority see SA1323 – Retail pharmacy				
	Tab 5 mg	CBS	50	✓ Zaroxolyn	\$29
61	HYDRALAZINE HYDROCHLORIDE – Special Authority see SA1321 – Retail pharmacy				
	* Tab 25 mg	CBS	56	✓ Onelink	\$29
119	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE				
	Inj 2%, 5 ml – Up to 5 inj available on a PSO.....	6.90	25	✓ Lidocaine-Clarix	
	Inj 2%, 20 ml – Up to 5 inj available on a PSO.....	2.40	1	✓ Lidocaine-Clarix	
186	PHARMACY SERVICES – May only be claimed once per patient				
	Brand switch fee	4.33	1 fee	✓ BSF Apo-Diltiazem CD	
	The Pharmacode for BSF Apo-Diltiazem CD is 2437775				

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions

Effective 1 May 2013

52 PERINDOPRIL

Perindopril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%."

* Tab 2 mg – Higher subsidy of \$18.50 per 30 tab with Endorsement.....	3.75 (18.50)	30	✓ Apo-Perindopril Coversyl
* Tab 4 mg – Higher subsidy of \$25.00 per 30 tab with Endorsement.....	4.80 (25.00)	30	✓ Apo-Perindopril Coversyl

52 TRANDOLAPRIL

Higher subsidy by endorsement is available Trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors **trandolapril** for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". Definition of Congestive Heart Failure At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the past required concomitant treatment with a diuretic. The definition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%." **For the purposes of this endorsement, congestive heart failure includes patients post myocardial infarction with an ejection fraction of less than 40%. Patients who started on trandolapril after 1 June 1998 are not eligible for full subsidy by endorsement.**

* Cap 1 mg – Higher subsidy of \$18.67 per 28 cap with Endorsement.....	3.06 (18.67)	28	Gopten
* Cap 2 mg – Higher subsidy of \$27.00 per 28 cap with Endorsement.....	4.43 (27.00)	28	Gopten

57 DILTIAZEM HYDROCHLORIDE

* Cap long-acting 120 mg – Brand switch fee payable (Pharmacode 2437775).....	31.83	500	✓ Apo-Diltiazem CD
* Cap long-acting 180 mg – Brand switch fee payable (Pharmacode 2437775).....	47.67	500	✓ Apo-Diltiazem CD
* Cap long-acting 240 mg – Brand switch fee payable (Pharmacode 2437775).....	63.58	500	✓ Apo-Diltiazem CD

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
-----------------------------------------------------------	---------------------------------	-----	------------------------------------------------

Changes to Restrictions - effective 1 May 2013 (continued)

91	CIPROFLOXACIN – Subsidy by endorsement 1) Subsidised only if: a) Patient has: i) microbiologically confirmed and clinically significant pseudomonas infection; or ii) prostatitis; or iii) pyelonephritis; or iv) gonorrhoea; b) Prescription or PSO is written by, or on the recommendation of, an infectious disease physician or a clinical microbiologist; and 2) The prescription or PSO is endorsed accordingly. Recommended for patients with the any of the following: i) microbiologically confirmed and clinically significant pseudomonas infection; or ii) prostatitis; or iii) pyelonephritis; or iv) gonorrhoea; or			
	Tab 250 mg – Up to 5 tab available on a PSO	2.20	28	✓ Cipflox
	Tab 500 mg – Up to 5 tab available on a PSO	3.00	28	✓ Cipflox
		10.71	100	✓ Cipflox
	Tab 750 mg	5.15	28	✓ Cipflox
		5.52	30	✓ Ciprofloxacin Rex
92	CLINDAMYCIN Cap hydrochloride 150 mg – Maximum of 4 cap per prescription; can be waived by endorsement – Retail pharmacy-Specialist... 9.90 Specialist must be an infectious disease physician or a clinical microbiologist Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy-Specialist... 160.00 Prescriptions must be written by, or on the recommendation of, an infectious disease physician or a clinical microbiologist.		16	✓ Clindamycin ABM
			10	✓ Dalacin C
94	ITRACONAZOLE Cap 100 mg – Subsidy by endorsement 4.25 Funded for tinea vesicolor where topical treatment has not been successful and diagnosis has been confirmed by mycology, or for tinea unguium where terbinafine has not been successful in eradication or the patient is intolerant to terbinafine and diagnosis has been confirmed by mycology and the prescription is endorsed accordingly. Can be waived by endorsement - Retail pharmacy - Specialist. Specialist must be an infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist.		15	✓ Itrazole
96	ISONIAZID – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation of, an internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician			
	* Tab 100 mg	20.00	100	✓ PSM
	* Tab 100 mg with rifampicin 150 mg	90.04	100	✓ Rifinah
	* Tab 150 mg with rifampicin 300 mg	179.57	100	✓ Rifinah
119	LIGNOCAINE HYDROCHLORIDE LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE Viscous soln 2%..... 55.00 Inj 1%, 5 ml – Up to 5 inj available on a PSO 35.00 Inj 2%, 5 ml – Up to 5 inj available on a PSO 23.00 6.90 Inj 1%, 20 ml – Up to 5 inj available on a PSO 20.00 Inj 2%, 20 ml – Up to 5 inj available on a PSO 15.00 2.40		200 ml 50 50 25 5 5 1	✓ Xylocaine Viscous ✓ Xylocaine ✓ Xylocaine ✓ Lidocaine-Clarix ✓ Xylocaine ✓ Xylocaine ✓ Lidocaine-Clarix

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price

Effective 1 May 2013

52	PERINDOPRIL (↑ subsidy)			
	Tab 2 mg	3.75	30	
		(18.50)		Coversyl
	Tab 4 mg	4.80	30	
		(25.00)		Coversyl
66	CALAMINE (↑ price)			
	a) Only on a prescription			
	b) Not in combination			
	Crn, aqueous, BP	1.77	100 g	
		(3.80)		Home Essential
78	LEVONORGESTREL (↓ subsidy)			
	* Tab 1.5 mg	3.50	1	✓ Postinor-1
	a) Maximum of 2 tab per prescription			
	b) Up to 5 tab available on a PSO			
120	CODEINE PHOSPHATE (↓ subsidy) – Safety medicine; prescriber may determine dispensing frequency			
	Tab 15 mg	4.75	100	✓ PSM
	Tab 30 mg	5.80	100	✓ PSM
	Tab 60 mg	12.50	100	✓ PSM
132	AMISULPRIDE (↓ subsidy) – Safety medicine; prescriber may determine dispensing frequency			
	Tab 100 mg	6.22	30	✓ Solian
	Tab 200 mg	21.92	60	✓ Solian
	Tab 400 mg	44.52	60	✓ Solian
	Oral liq 100 mg per ml	52.50	60 ml	✓ Solian

Changes to General Rules

Effective 1 May 2013

- 18 3.3 Original Packs, Certain Antibiotics and Unapproved Medicines
- 3.3.2 If a Community Pharmaceutical is either:
- the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing; or
 - an unapproved medicine supplied under Section 29 of the Medicines Act 1981 **excluding any medicine listed as Cost, Brand, Source of Supply**, and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where:
 - the difference the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100 ml pack would be dispensed); and
 - in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner.

Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

Effective 1 April 2013

- 13 "Hospital Pharmacy-Specialist" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an Outpatient either:
- on a Prescription signed by a Specialist, or
 - where the treatment with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a practitioner which is either:
 - endorsed with the words "recommended by [name of specialist and year of authorisation]" and signed by the Practitioner, or
 - endorsed with the word 'protocol' which means "initiated in accordance with DHB hospital approved protocol"**,
 - annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and date of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as **either**:

- follows a substantive consultation with an appropriate Specialist;
 - the consultation to relate to the Patient for whom the Prescription is written;
 - consultation to mean communication by referral, telephone, letter, facsimile or email;
 - except in emergencies consultation to precede annotation of the Prescription; and
 - both the specialist and the General Practitioner must keep a written record of the consultation; **or**
- treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol**

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to General Rules – effective 1 April 2013 (continued)

- 15 “Retail Pharmacy-Specialist” means that the Community Pharmaceutical is only eligible for Subsidy if it is either:
- a) supplied on a Prescription or Practitioner’s Supply Order signed by a Specialist, or,
 - b) in the case of treatment recommended by a Specialist, supplied on a Prescription or Practitioner’s Supply Order and either:
 - i) endorsed with the words “recommended by [name of Specialist and year of authorisation]” and signed by the Practitioner, or
 - ii) **endorsed with the word ‘protocol’ which means “initiated in accordance with DHB hospital approved protocol”, or**
 - iii) Annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words “recommended by [name of specialist and year of authorisation], confirmed by [practitioner]”. Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

“As recommended by a Specialist” to be interpreted as **either**:

- 1)
 - a) follows a substantive consultation with an appropriate Specialist;
 - b) the consultation to relate to the Patient for whom the Prescription is written;
 - c) consultation to mean communication by referral, telephone, letter, facsimile or email;
 - d) except in emergencies consultation to precede annotation of the Prescription; and
 - e) both the Specialist and the General Practitioner must keep a written record of consultation; **or**
- 2) **treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.**

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Brand Name

Effective 1 May 2013

85	LEVOTHYROXINE				
	Tab 50 mcg	1.71	28	✓ Goldshield	Mercury Pharma
	‡ Safety cap for extemporaneously compounded oral liquid preparations.				
	Tab 100 mcg.....	1.78	28	✓ Goldshield	Mercury Pharma
	‡ Safety cap for extemporaneously compounded oral liquid preparations.				

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Changes to Section I

Effective 1 May 2013

224	INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj	90.00	10	✓ Fluarix ✓ Fluvax
-----	-------------------------------------------------------------	-------	----	-------------------------------------

A) is available each year for patients who meet the following criteria, as set by PHARMAC:

- a) all people 65 years of age and over;
- b) people under 65 years of age **with who**:
 - i) **have** the following cardiovascular disease:
 - 1) ischaemic heart disease,
 - 2) congestive heart disease,
 - 3) rheumatic heart disease,
 - 4) congenital heart disease, or
 - 5) cerebo-vascular disease;
 - ii) **have** the following chronic respiratory disease:
 - 1) asthma, if on a regular preventative therapy, or
 - 2) other chronic respiratory disease with impaired lung function;
 - ~~iii) are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness.~~
 - ~~iii) **have** diabetes;~~
 - ~~iv) **have** chronic renal disease;~~
 - ~~v) **have** any cancer, excluding basal and squamous skin cancers if not invasive;~~
 - ~~vi) **have any of the following other conditions**:

 - a) autoimmune disease,
 - b) immune suppression,
 - c) HIV,
 - d) transplant recipients,
 - e) neuromuscular and CNS diseases,
 - f) haemoglobinopathies, or
 - g) **are** children on long term aspirin; **or**~~
 - ~~vii) **are pregnancy pregnant**.~~
- c) people under 18 years of age living within the boundaries of the Canterbury District Health Board
- d) are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness**

Unless meeting other the criteria above, the following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
- b) hypertension and/or dyslipidaemia without evidence of end-organ disease.

B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.

C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor.

D) Stock of the seasonal influenza vaccine is typically available from February until late July with suppliers being required to ensure supply until at least 30 June. Exact start and end dates for each season will be notified each year.

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items

Effective 1 May 2013

24	CALCIUM CARBONATE WITH AMINOACETIC ACID * Tab 420 mg with aminoacetic acid 180 mg – Higher subsidy of \$6.30 per 100 tab with Endorsement	3.00 (6.30)	100		Titralac
	Additional subsidy by endorsement is available for pregnant women. The prescription must be endorsed accordingly.				
40	MICONAZOLE Oral gel 20 mg per g	4.95 (8.70)	40 g OP		Daktarin
47	RIVAROXABAN – Special Authority see SA1066 – Retail pharmacy Tab 10 mg	306.00	30	✓	Xarelto
57	DILTIAZEM HYDROCHLORIDE Cap long-acting 120 mg	1.91 (4.34)			Cardizem CD
	Cap long-acting 180 mg	2.86 (6.50)			Cardizem CD
	Cap long-acting 240 mg	3.81 (8.67)			Cardizem CD
63	SILDENAFIL – Special Authority see SA1293 – Retail pharmacy Tab 25 mg	39.00	4	✓	Viagra
	Tab 50 mg	43.50	4	✓	Viagra
	Tab 100 mg – For sildenafil oral liquid formulation refer, page 179	47.00	4	✓	Viagra
72	CALCIPOTRIOL Oint 50 mcg per g	20.20	30 g OP	✓	Daivonex
	Soln 50 mcg per ml	33.79	60 ml OP	✓	Daivonex
89	AZITHROMYCIN – Maximum of 5 days treatment per prescription; can be waived by endorsement For Endorsement, patient has either: i) Received a lung transplant and requires treatment or prophylaxis for bronchiolitis obliterans syndrome *; or ii) Cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms * Indications marked with * are Unapproved Indications Tab 500 mg – Up to 8 tab available on a PSO	1.25	2 OP	✓	Arrow-Azithromycin
113	PAMIDRONATE DISODIUM Inj 3 mg per ml, 10 ml	16.00 (37.50)	1		Pamisol
	Inj 6 mg per ml, 10 ml	32.00 (75.00)	1		Pamisol
	Inj 9 mg per ml, 10 ml	48.00 (112.50)	1		Pamisol

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ **fully subsidised**

Delisted Items – effective 1 May 2013 (continued)

185	TYLOXAPOL * Eye drops 0.25%	8.63	15 ml OP	✓ <u>Enuclene</u>
212	AMINO ACID FORMULA – Special Authority see SA1219 – Hospital pharmacy [HP3] Powder (tropical)	53.00	400 g OP	✓ Neocate Advance

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted

Effective 1 August 2013

186 PHARMACY SERVICES - May only be claimed once per patient
* Brand switch fee..... 4.33 1 fee ✓ **BSF Apo-Diltiazem CD**

Effective 1 November 2013

181 SODIUM CROMOGLYCATÉ
Nasal spray, 4% 15.85 22 ml OP ✓ **Rex**

211 AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA1108 – Hospital pharmacy [HP3]
Sachets (tropical) 324.00 30 ✓ **Phlexy 10**

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Section H page ref	Price (ex man. excl. GST)		Brand or Generic Manufacturer
	\$	Per	

Section H changes to Part II

Effective 1 May 2013

16	AMISULPRIDE (↓ price and addition of HSS)			
	Tab 100 mg – 1% DV Jul-13 to 2016	6.22	30	Solian
	Tab 200 mg – 1% DV Jul-13 to 2016	21.92	60	Solian
	Tab 400 mg – 1% DV Jul-13 to 2016	44.52	60	Solian
	Oral liq 100 mg per ml – 1% DV Jul-13 to 2016	52.50	60 ml	Solian
17	AMOXYCILLIN (delisting)			
	Drops 100 mg per ml.....	4.00	30 ml	Ospamox
	Note – Ospamox drops 100 mg per ml to be delisted from 1 July 2013			
22	CEFOTAXIME (delisting)			
	Inj 2 g.....	2.60	1	Cefotaxime Sandoz
	Note – Cefotaxime Sandoz inj 2 g to be delisted from 1 July 2013			
25	CLONIDINE HYDROCHLORIDE			
	Tab 25 mcg – 1% DV Jul-13 to 2015	15.09	112	Clonidine BNM
	Note – Dixarit tab 25 mcg to be delisted 1 July 2013			
26	CODEINE PHOSPHATE (↓ price and addition of HSS)			
	Tab 15 mg – 1% DV Jul-13 to 2016	4.75	100	PSM
	Tab 30 mg – 1% DV Jul-13 to 2016	5.80	100	PSM
	Tab 60 mg – 1% DV Jul-13 to 2016	12.50	100	PSM
29	DORIPENEM (delisting)			
	Vial for infusion 500 mg.....	454.50	10	Doribax
	Note – Doribax vial for infusion 500 mg to be delisted from 1 July 2013			
42	LEVONORGESTREL			
	Tab 1.5 mg – 1% DV Jul-13 to 2016	3.50	1	Postinor-1
	Note – Next Choice tab 750 mcg to be delisted 1 July 2013			
42	LIGNOCAINE HYDROCHLORIDE LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (amended chemical name)			
	Pump spray 10%, 50 ml CFC-free			
	– 1% DV Nov-10 to 2013	75.00	50 ml	Xylocaine
	Viscous soln 2% – 1% DV Sep-11 to 2014	55.00	200 ml	Xylocaine Viscous
	Inj 1%, 2 ml.....	57.60	50	Xylocaine
	Inj 1%, 5 ml.....	35.00	50	Xylocaine
	Inj 1%, 5 ml – 1% DV Jul-13 to 2015	8.75	25	Lidocaine-Clarix
	Inj 1%, 20 ml.....	20.00	5	Xylocaine
	Inj 1%, 20 ml – 1% DV Jul-13 to 2015	2.40	1	Lidocaine-Clarix
	Inj 2%, 2 ml.....	62.40	50	Xylocaine
	Inj 2%, 5 ml.....	23.00	50	Xylocaine
	Inj 2%, 5 ml – 1% DV Jul-13 to 2015	6.90	25	Lidocaine-Clarix
	Inj 2%, 20 ml.....	15.00	5	Xylocaine
	Inj 2%, 20 ml – 1% DV Jul-13 to 2015	2.40	1	Lidocaine-Clarix
	Note – Xylocaine inj 1% 2 ml, 1% 5 ml, 1% 20 ml, 2% 2 ml, 2% 5 ml, 2% 20 ml to be delisted 1 July 2013.			
46	MICONAZOLE NITRATE (delisting)			
	Powder 2%.....	8.50	30 g	Daktarin
	Note – Daktarin powder 2% to be delisted from 1 July 2013			

Products with Hospital Supply Status (HSS) are in **bold**.

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref	Price (ex man. excl. GST) \$ Per	Brand or Generic Manufacturer
--------------------	----------------------------------------	-------------------------------------

Section H changes to Part II – effective 1 May 2013 (continued)

7	MORPHINE SULPHATE (delisting) Inj 1 mg per ml, 30 ml prefilled syringe 75.00 10 Note - Biomed inj 1 mg per ml, 30 ml prefilled syringe to be delisted from 1 July 2013.	Biomed
52	PERINDOPRIL Tab 2 mg 3.75 30 Tab 4 mg 4.80 30	Apo-Perindopril Apo-Perindopril
55	PROPOFOL (delisting) Inj 2%, 50 ml prefilled syringe 60.00 1 Note – Diprivan Inj 2%, 50 ml prefilled syringe to be delisted from 1 July 2013.	Diprivan
57	RETINOL PALMITATE (delisting) Oint 25 g 2.00 1 Oint 50 g 2.86 1 Note – PSM and healthE oint 25 g and 50 g to be delisted from 1 July 2013.	PSM healthE
61	SODIUM HYALURONATE (amendment to line item description) Ophthalmic inj 14 mg per ml, 0.55 ml – 1% DV Oct-12 to 2015 50.00 1 Ophthalmic inj 14 mg per ml, 0.85 ml – 1% DV May-13 to 2015 50.00 1 Note – Clarification of line description with a new Pharmacode applied to the new presentation.	Healon GV Healon GV
61	SORBOLENE WITH GLYCERIN (↓ price) Crm with 10% glycerine, 100 g 2.72 1 Crm with 10% glycerine, 500 ml 5.46 1	healthE healthE

Effective 1 April 2013

18	BACLOFEN (↓ price and addition of HSS) Tab 10 mg - 1% DV Jun-13 to 2016 3.85 100	Pacifen
19	BENZBROMARONE Tab 100 mg 45.00 100	Benzbromaron
19	BISMUTH TRIOXIDE Tab 120 mg 32.50 112	De-Nol
24	CHLORTHALIDONE (delisting) Tab 25 mg 4.80 30 Note – Igroton tab 25 mg to be delisted from 1 June 2013	Igroton
28	DIAZOXIDE Cap 25 mg 110.00 100 Cap 100 mg 280.00 100	Proglicem Proglicem

Products with Hospital Supply Status (HSS) are in **bold**.
Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref	Price (ex man. excl. GST) \$ Per	Brand or Generic Manufacturer
--------------------	----------------------------------------	-------------------------------------

Section H changes to Part II – effective 1 April 2013 (continued)

29	DOCETAXEL (new listing and change to HSS)			
	Inj 20 mg – 1% DV Sep-11 to 30 April 2013	48.75	1	Docetaxel Ebewe
	Inj 20 mg – 1% DV May-13 to 2014	48.75	1	Docetaxel Sandoz
	Inj 80 mg – 1% DV Sep-11 to 30 April 2013	195.00	1	Docetaxel Ebewe
	Inj 80 mg – 1% DV May-13 to 2014	195.00	1	Docetaxel Sandoz
37	GLYCERYL TRINITRATE			
	Oint 0.2%	22.00	30g	Rectogesic
37	HIGH FAT LOW CARBOHYDRATE FORMULA			
	Powder (vanilla) (amendment to brand name)	35.50	300 g	KetoCal 4:1
	Powder (unflavoured)	35.50	300 g	KetoCal 3:1
50	NITAZOXANIDE			
	Tab 500 mg	1680.00	30	Alinia
50	NORTRIPTYLINE HYDROCHLORIDE (↓ price and addition of HSS)			
	Tab 10 mg - 1% DV Jun-13 to 2016	4.00	100	Norpress
	Tab 25 mg - 1% DV Jun-13 to 2016	9.00	180	Norpress
52	OXYBUTYNIN (addition of HSS)			
	Tab 5 mg - 1% DV Jun-13 to 2016 (↓ price)	11.20	500	Apo-Oxybutynin
	Oral liq 5 mg per 5 ml - 1% DV Jun-13 to 2016 (↑ price)	56.45	473 ml	Apo-Oxybutynin
53	PARA-AMINO SALICYLIC ACID			
	Grans for oral liq 4 g sachet	280.00	30	Paser
53	PAROMOMYCIN			
	Cap 250 mg	126.00	16	Humatin
53	PEGASPARGASE			
	Inj 3,750 IU per 5 ml	3,005.00	1	Oncaspar
56	PROTIONAMIDE			
	Tab 250 mg	305.00	100	Peteha
63	STIRIPENTOL			
	Cap 250 mg	509.29	60	Diacomit
	Powder for oral liq 250 mg sachet	509.29	60	Diacomit
63	TETRACYCLINE			
	Cap 500 mg	46.00	30	Tetracyclin Wolff

Products with Hospital Supply Status (HSS) are in **bold**.

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Index

Pharmaceuticals and brands

A	
Alinia	32
Amino acid formula	28
Aminoacid formula without phenylalanine	29
Amisulpride	22, 30
Amoxicillin	30
Apo-Diltiazem CD	20
Apo-Oxybutynin	32
Apo-Perindopril	19, 20, 31
Arrow-Azithromycin	27
Azithromycin	27
B	
Baclofen	31
Benzbromaron	31
Benzbromarone	31
Bismuth trioxide	31
BSF Apo-Diltiazem CD	19, 29
C	
Calamine	22
Calcipotriol	27
Calcium carbonate with aminoacetic acid	27
Cardizem CD	27
Cefotaxime	30
Cefotaxime Sandoz	30
Chlorthalidone	31
Ciproflox	21
Ciprofloxacin	21
Ciprofloxacin Rex	21
Clindamycin	21
Clindamycin ABM	21
Clonidine BNM	19, 30
Clonidine hydrochloride	19, 30
Codeine phosphate	22, 30
Coversyl	20, 22
D	
Daivonex	27
Daktarin	27, 30
Dalacin C	21
De-Nol	31
Diacomit	32
Diazoxide	31
Diltiazem hydrochloride	20, 27
Diprivan	31
Docetaxel	32
Docetaxel Ebewe	32
Docetaxel Sandoz	32
Doribax	30
Doripenem	30
E	
Enuclele	28
F	
Fluarix	26
Fluvax	26
G	
Glyceryl trinitrate	32
Gopten	20
H	
Healon GV	31
High fat low carbohydrate formula	32
Home Essential	22
Humatin	32
Hydralazine hydrochloride	19
I	
Igroton	31
Influenza vaccine	26
Isoniazid	21
Itraconazole	21
Itrazole	21
K	
KetoCal 3:1	32
KetoCal 4:1	32
L	
Levonorgestrel	22, 30
Levothyroxine	25
Lidocaine-Clarix	19, 21, 30
Lidocaine [lignocaine] hydrochloride	19, 21, 30
Lignocaine hydrochloride	21, 30
M	
Metolazone	19
Miconazole	27
Miconazole nitrate	30
Morphine sulphate	31
N	
Neocate Advance	28
Nitazoxanide	32
Norpress	32
Nortriptyline hydrochloride	32
O	
Oncaspar	32
Ospamox	30
Oxybutynin	32
P	
Pacifen	31
Pamidronate disodium	27
Pamisol	27
Para-amino salicylic acid	32
Paromomycin	32
Paser	32
Pegaspargase	32
Perindopril	19, 20, 22, 31
Peteha	32
Pharmacy services	19, 29
Phlexy 10	29
Postinor-1	22, 30

Index

Pharmaceuticals and brands

Proglicem	31	T	
Propofol.....	31	Tetracycline	32
Protionamide.....	32	Tetracyclin Wolff	32
R		Titralac	27
Rectogesic.....	32	Trandolapril.....	20
Retinol palmitate	31	Tyloxapol	28
Rifinah	21	V	
Rivaroxaban.....	27	Viagra	27
S		X	
Sildenafil.....	27	Xarelto	27
Sodium cromoglycate	29	Xylocaine	21, 30
Sodium hyaluronate	31	Xylocaine Viscous	21, 30
Solian	22, 30	Z	
Sorbolene with glycerin	31	Zaroxolyn	19
Stiripentol	32		

Index

Pharmaceuticals and brands

Index

Pharmaceuticals and brands

New Zealand
Permit No. 478



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand


Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

Freephone Information line (9am-5pm weekdays) 0800 66 00 50

ISSN 1172-9376 (Print)

ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.



New Zealand Government

PHARMAC
Pharmaceutical Management Agency

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand